Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dahlöf, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dahlöf, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


End-organ damage: does it really matter how we prevent it?

B. Dahlöf*

Sahlgrenska University Hospital/Östra, Göteborg, Sweden

* Björn Dahlöf, MD, Department of Medicine, Ostral Hospital, SE-41685 Göteborg, Sweden

Abstract

Studying left ventricular hypertrophy (LVH) allows the most comprehensive evaluation of end-organ damage prevention. Clinical trials show that renin-angiotensin-aldosterone system blockade confers protective effects that are not simply due to antihypertensive activity. Angiotensin II receptor blockers (ARBs), which offer specific and complete inhibition of the action of angiotensin II at the level of the angiotensin II type 1 (AT1) receptor, have proves more effective than other antihypertensive classes in reversing LVH and interstitial collagen accumulation. The Losartan Intervension For Endpoint reduction in hypertension (LIFE) study, for example, showed that a losartan-based therapy resulted in better LVH regression than an atenolol-based one, despite similar blood pressure control with both treatment regimens. Other clinical studies demonstrated that ARB-induced reduction in fibrosis is linked to functional improvement. It is still not known whether more effective angiotensin II blockade will provide more complete LVH reversal, improve cardiac function, prevent damage to other target organs and enhance prognosis. To find the answer, The ONgoing Telmisartan Alone and in combination with Ramipril GLobal Endpoint Trial (ONTSRGET) Trial Programme will compare 24-h active AT1 blockade with telmisartan versus established angiotensin-converting enzyme (ACE) inhibition using ramipril versus AT1 blockade plus ACE inhibition.

Key Words: Endotheliall dysfunction • Left ventricular hypertrophy • Renin-angiotensin-aldosterone system • Target organ damage • Treatment

References

  1. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the ‘rule oe halves’ stil valid? J Hum Hypertens. 1997;11:213–220[CrossRef][Web of Science][Medline]
  2. Smith WC, Lee AJ, Crombie IK, et al. Control of blood pressure in Scotlant: the rule of halves. BMJ. 1990;300:981–983
  3. Pannarale G, Gaudio C, Cristina Acconcia M, et al. Results of antihypertensive treatment by primary and secondary care physicians as assessed by ambulatory blood pressure monitoring. Blood Press Monit. 2000;5:223–226[Medline]
  4. Cruickshank JK, Mbanyan JC, Wilks R, et al. Hypertension in four African-origin populations: current ‘rulel of halves’, quality of blood pressure control and attributable risk of cardiovascular disease. J Hypertens. 2001;19:41–46[CrossRef][Web of Science][Medline]
  5. Weinehall L, Ohgren B, Persson M, et al. High remainung risk in poorly treated hypertension: the ‘rule of halves’ still exists. J Hypertens. 2002;20:2081–2088[CrossRef][Web of Science][Medline]
  6. Teo KK. Risak and management of hypertension-related left ventricular hypertrophy. Drugs. 1995;50:959–970[Medline]
  7. Swales JD. Current clinical practice in hypertensionL the EISBERG (Evaluation and Interventions for Systlic Blood pressure Elevation-Regional and Global) project. Am Heart J. 1999;138:S231–S237 (3 Pt 2)
  8. Weir MR. When antihypertensive monotherapy fails: fixed-dose combination therapy. South Med J. 2000;93:548–556[Medline]
  9. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95–110[Web of Science][Medline]
  10. Zhu YC, Zhu YZ, Gohlke P, et al. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism onc ardiac parameters in left ventricular hypertrophy. Am J Cardiol. 1997;80(suppl A):110A–117A[CrossRef][Medline]
  11. Dahlöf B, Devereux R, de Faire U, et al. The Losartan intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens. 1997;10:705–713[CrossRef][Web of Science][Medline]
  12. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003[CrossRef][Web of Science][Medline]
  13. Okin PM, Devereux RB, Jern S, et al. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens. 2001;14:775–782[Medline]
  14. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervension For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010[CrossRef][Web of Science][Medline]
  15. Dahlöf B, Zanchetti A, Diez J, et al. Effect of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20:1855–1864[CrossRef][Web of Science][Medline]
  16. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729–1735[Abstract/Free Full Text]
  17. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512–2517[Abstract/Free Full Text]
  18. Mesfin GM, Piper RC, DuCharme DW, et al. Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol. 1989;17:164–181[Web of Science][Medline]
  19. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388–1393[Abstract/Free Full Text]
  20. Ikeda Y, Nakamura T, Takano H, et al. Angiotensin II-induced cardiomyocyte hypetrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. J Lab Clin Med. 2000;135:353–359[Medline]
  21. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167–1176[CrossRef][Web of Science][Medline]
  22. Isobe N, Taniguchi K, Oshima S, et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J. 2002;66:993–999[Medline]
  23. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens. 2001;14:174–182[CrossRef][Medline]
  24. Wienen W, Entzeroth M, Diederen W, et al. Pharmacology and antihypertensive effects of telmisartan an AT1-selective angiotensin II receptor antagonist. 1997, London1st International Symposium on Angiotensin II Antagonism. 28 September–1st October 1997.
  25. Maillard MP, Perregaux C, Centero C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insumountable angiotensin II receptor antagonist. J Pharmacol Exp Ther. 2002;302:1089–1095[Abstract/Free Full Text]
  26. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press. 2001;10(suppl 1):6–11[Web of Science][Medline]
  27. Stangier J, Su C-APF, van Heiningen PNM, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol. 2001;38:672–685[CrossRef][Medline]
  28. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001;61:1501–1529[CrossRef][Web of Science][Medline]
  29. Smith DHG, Amtzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 2000;40:1380–1390[Abstract]
  30. White W. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens. 2003;: (in press0
  31. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptor. [abstract P1.24]J Hypertens. 2001;19(suppl 2):S27
  32. Böhm M, Lippoldt A, Wienen W, et al. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem. 1996;163/164:217–221
  33. Wagner J, Drab M, Bohlender J, et al. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertesnive rats of the stroke prone strain. Clin Exp Hypertens. 1998;20:205–221
  34. Wienen W, Richard S, Champeroux P, et al. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Antiogensin Aldosterone Syst. 2001;2:31–36
  35. Amende I, Chu V, Morgan JP, et al. Angiotensin II AT1 receptor blockade attenuates isoproterenol-induced cardiac hypertrophy in mice. [abstract P2161]Eur HEart J. 2000;21:401 (abstract suppl)
  36. Mattioli AV, Fontanesi L, Bonatti S, et al. Effects of regression of left ventricular hypetrophy on diastolic function in hypertensive patients. Am J Hypertens. 2002;15(suppl 1):A44
  37. Petrovic J, Popovic Z, Petrovic D, et al. Telmisartan: influence on endothelial dysfunction in hypertensive patients. [abstract Pa.17]J Renin Angiotensin Aldosterone Syste. 2000;1:74
  38. Petrovic J, Petrovic M, Petrasinovic Z, et al. Ventricular and vascular remodeling: effects inhibitors ACE and All receptor antagonists in hypertensive patients. [abstract]Atherosclerosis. 2000;151:229
  39. Ivanova OV, Fomicheva OA, Sergakova LM, et al. Angiotensin II receptor blockder telmisartan: effect on 24-hour blood pressure profile and left ventricular hypetrophy in patients with hypertension. Kardiologiia. 2002;42:45–49
  40. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared ti echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995;8:221–228[CrossRef][Web of Science][Medline]
  41. Willeit J, Kiechl S. Biology of arterial atheroma. Cerebrovasc Dis. 2000;10(suppl 5):1–8
  42. Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit. 2001;7:1075–1085[Medline]
  43. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 20002;106:672–678
  44. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869[Abstract/Free Full Text]
  45. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellisus: a placebo-controlled trial. Curr Ther Res. 1999;60:650–660[CrossRef]
  46. Mancia G, Carugo S, Grassi G, et al. Prevalance of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002;39:744–749[Abstract/Free Full Text]
  47. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challanges in improving prognosis. Am J Cardiol. 2002;89(suppl 2A):18A–25A[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dahlöf, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dahlöf, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?